Please ensure Javascript is enabled for purposes of website accessibility

Cantel Medical Corp. Keeps Pace on Its Goal

By Brian Orelli, PhD – Dec 8, 2017 at 4:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A solid first fiscal quarter puts the medical-supply company on pace to meet its 2018 guidance.

Cantel Medical (CMD) reported results for the first quarter, posting double-digit revenue and earnings growth to start its fiscal year. It's hard to ask for more from the medical-supply company.

Cantel Medical results: The raw numbers


Q1 2018

Q1 2017

Year-Over-Year Change


$212.8 million

$187.7 million


Income from operations

$31.6 million

$27.1 million


Earnings per share




Data source: Cantel Medical.

What happened with Cantel Medical this quarter?

  • Sales of endoscopy products led the group with revenue growth of 19.8%. Some of that came from the addition of BHT, a German company Cantel acquired in August. But even backing out acquisitions, endoscopy sales of grew 10.7% organically. A lot of the growth is coming from the installed base of endoscopy machines driving recurring revenue, which increased 20.8% year over year.
  • Water purification and filtration sales increased 7.4%, and the unit still has a backlog of $66 million worth of products that have been ordered but need to be shipped and installed.
  • Sales of healthcare disposables increased 5.7%, but income from the segment increased at a higher rate thanks to higher-margin branded products.
  • The company generated $30.1 million in cash from operations, up 20.7% year over year, helping it pay down $19.3 million of debt. Net debt now sits at $130.8 million.
Gloved hands of a doctor using an endoscope

Image source: Getty Images.

What management had to say

Jorgen Hansen, Cantel's president and CEO, said the company isn't done making acquisitions yet and hinted they could come sooner rather than later:

From an M&A perspective, we are very encouraged with the health of our pipeline and are optimistic about potential deals in the coming quarters. We are evaluating opportunities to acquire new businesses and technologies in all of our existing segments, as well as exploring potential new verticals within infection prevention.

Hansen also highlighted some new products the company is working on to boost revenue organically:

We have new line extensions on the procedure side in endoscopy, which obviously is very important since this is a high-growth, high-profit area. We are planning to launch new [inaudible] water systems and portable water systems in our water business, and we are adding a couple of new products in health disposables or dental business, as well as in the consumables side of the business with some new technologies and great markets. So we feel really good about the pipeline and our ability to continue to drive organic growth through our commercial teams.

Looking forward

Management is sticking with guidance for its current fiscal year that was given when it reported last quarter. Revenue should grow between 12.5% and 13.5%, with earnings per share (EPS) expected to grow by 20% to 25% while adjusted EPS will should increase only 10% to 13%.

As long as Cantel can keep doing what it did in the first fiscal quarter, it should be able to hit those goals.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool recommends Cantel Medical. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cantel Medical Corp. Stock Quote
Cantel Medical Corp.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.